The Use of Surgical Pleth Index in Guiding Anesthesia in Gastroenterological Surgery

Sponsor
Tampere University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04519203
Collaborator
general electric healthcare Finland (Other)
80
1
2
13.7
5.8

Study Details

Study Description

Brief Summary

Surgical Pleth Index (SPI) is an intraoperative monitor aimed into detection of nociception and guidance of intraoperative opioid administration. Using such a device opioid administration could be potentially optimized during intraoperative period. this study will aim to show whether SPI could be used to reduce unwanted events and lower opioid consumption in gastroenterological surgery. The study will be blinded and randomized including two study arms with either SPI monitoring included or standard monitoring alone.

Condition or Disease Intervention/Treatment Phase
  • Device: SPI
  • Device: Standard
N/A

Detailed Description

Patients are extensively monitored intraoperatively. Even though there are monitors for the measurement of nociception, it has not gained wide acceptance partly because of limited and scarce evidence on the efficacy and optimal use. Especially elderly patients undergoing major operation might benefit from optimization of opioid administration. Surgical Pleth Index (SPI) is an intraoperative monitoring aimed for detection of nociceptive stimulus.

The aim of this research is to study whether SPI could be used to guide opioid administration in gastroenterological surgery. The study will consist of a total 80 patients which are randomized into two groups. The study sample is based on power calculation for the reduction of remifentanil consumption.

In the study group the opioid administration will be guided using a SPI based protocol. In the control group the opioid administration will be based on standard monitoring and clinical decision alone. The aim of the study will be to study whether opioid administration optimized using SPI can lover need for anticholinergic drugs, reduce need for opioids or diminish the amount of unwanted side effects postoperatively. The patients will be treated using target controlled infusions of remifentanil and propofol.

The data will be collected intraoperatively using electronic software and using a study data collection form by study personel. All study procedures will take place during operative period.

The study power was calculated using a study comparing depth of anesthesia and depth of nociception balance-controlled group into a group without these monitors. In the group with monitoring the consumption of remifentanil was 9,5±3.8 mg/kg/h while in the unmonitored group the consumption was 12.3 mg/kg/h(Chen, 2010). While taking into notice α= 0,005 and β=90% a number of 39 patients in each group is needed. Based on these we chose 80 patients to be included in the study.

All collected data will be used into statistical analysis ass applicable. Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

Study Design

Study Type:
Interventional
Actual Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
Patients are randomized using sealed envelopes. The ramdomization will be kept blinded to the study subjects
Primary Purpose:
Treatment
Official Title:
The Use of Surgical Pleth Index in Guiding Anesthesia in Gastroenterological Surgery
Actual Study Start Date :
Sep 9, 2020
Actual Primary Completion Date :
Nov 1, 2021
Actual Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: SPI group

Group of patients where opioid consumption will be guided using SPI target

Device: SPI
Either standard monitoring alone or added with SPI

Active Comparator: Control Group

Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period

Device: Standard
Standard monitoring alone

Outcome Measures

Primary Outcome Measures

  1. Intraoperative remifentanil consumption [intraoperative time]

    The consumption of the remifentanil intraoperatively

Secondary Outcome Measures

  1. severe hypotension [intraoperative time]

    MAP <55 mmHg, or -30% from the baseline value

  2. intermediate hypotension [intraoperative time]

    MAP <65 mmHg, or -20% from the baseline value

  3. hypertension [intraoperative time]

    RRsys >140 mmHg or +20 % from baseline value

  4. Bradycardia [intraoperative time]

    Heart rate<45

  5. tachycardia [intraoperative time]

    Heart rate>90

  6. Inraoperative propofol consumption [intraoperative time]

  7. Desorientation/ grade of sedation during postoperative care treatment [2-4 hours]

    The postoperative desoroentation during immediate post-operative period at postanesthesia care unit. Measured using modified aldrete score

  8. Postoperative nausea and vomiting [2-4 hours]

    The postoperative nausea and vomiting during immediate post-operative period at postanesthesia care unit. Measured using modified aldrete score.

  9. Postoperative opioid consumption [2-4 hours]

    The postoperative opioid consumption during immediate post-operative period at postanesthesia care unit.

  10. Fading of intraoperative relaxation [intraoperative time]

    The characteristics of intraoperative relaxation using EMG measurement

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Able to provide a written informed consent

  • Age 50 years or above

  • Laparoscopic or laparotomic surgery requiring intubation with an expected intraoperative time at least two hours.

  • ASA classification 1-3

Exclusion Criteria:
  • Implanted cardiac pacemaker or known condition with irregular heart rate at the time of inclusion or induction

  • Chronic use of opioids

  • BMI >35

  • Known allergy for study medications

  • Over 5 extrasystoles per minute at the time of induction or inclusion

  • The use of epidural catheter during the last one hour before surgery or need for catheter intraoperatively (if new catheter is placed at the beginning of surgery test dosage may be used without the need for patient exclusion)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tampere University Hospital Tampere Finland 33521

Sponsors and Collaborators

  • Tampere University Hospital
  • general electric healthcare Finland

Investigators

  • Principal Investigator: Jarkko Harju, MD, PhD, Tampere University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tampere University Hospital
ClinicalTrials.gov Identifier:
NCT04519203
Other Study ID Numbers:
  • R20006
First Posted:
Aug 19, 2020
Last Update Posted:
Nov 30, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Tampere University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 30, 2021